OPTIMIZED NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL COMPOSITIONS BASED THEREON WITH SUSTAINED VEGF TRANSGENE EXPRESSION Russian patent published in 2017 - IPC C12N15/12 C12N15/63 A61K48/00 

FIELD: biotechnology.

SUBSTANCE: way to extend the lifetime of vegf transgene mRNA in a mammal cell transfected with the genetic structure. Point deletions of 3'noncoding region of the vascular endothelial growth factor (Vegf) gene are performed, at that, the deleted nucleotide is not replaced or replaced by cytosine in guanine or adenine substitution points. Then, mRNA lifetime is determined for each deletion. Data is analyzed and a genetic structure is designed, comprising 3'noncoding region with aggregated single deletions and/or cytosine substitutions, which showed the best results in terms of mRNA lifetime extension. In addition, versions of plasmid DNA, constructed to implement the said method, and vegf transgene mRNA obtained by plasmid DNA transcription, are proposed. The invention also relates to plasmid DNA aplication, including its use as part of a pharmaceutical composition for tissue regeneration.

EFFECT: invention allows to increase overall therapeutic vegf protein production due to an increased mRNA lifetime achieved by introduction of optimal changes in the vegf gene 3'UTR sequence.

8 cl, 9 dwg, 2 tbl, 2 ex